阿巴卡韦在血浆和脑脊液中的群体药代动力学。
Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.
作者信息
Capparelli Edmund V, Letendre Scott L, Ellis Ronald J, Patel Parul, Holland Diane, McCutchan J Allen
机构信息
Pediatric Pharmacology Research Unit (PPRU), University of California, San Diego, 200 West Arbor Drive, MC 8214, San Diego, CA 92103-8214, USA.
出版信息
Antimicrob Agents Chemother. 2005 Jun;49(6):2504-6. doi: 10.1128/AAC.49.6.2504-2506.2005.
Abstract
The distribution of abacavir into the cerebrospinal fluid (CSF) was assessed by use of a population pharmacokinetic analysis. Plasma and CSF abacavir concentrations in 54 subjects were determined. The abacavir CSF/plasma ratio averaged 36% and increased throughout the dose interval. Abacavir penetrates into the CSF in adequate concentrations to inhibit local human immunodeficiency virus replication.
摘要
通过群体药代动力学分析评估了阿巴卡韦在脑脊液（CSF）中的分布情况。测定了54名受试者血浆和脑脊液中的阿巴卡韦浓度。阿巴卡韦的脑脊液/血浆平均比值为36%，且在整个给药间隔期间升高。阿巴卡韦以足够的浓度渗透到脑脊液中，以抑制局部人类免疫缺陷病毒的复制。
相似文献
1
Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.阿巴卡韦在血浆和脑脊液中的群体药代动力学。
Antimicrob Agents Chemother. 2005 Jun;49(6):2504-6. doi: 10.1128/AAC.49.6.2504-2506.2005.
2
Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study.[(14)C]阿巴卡韦（一种1型人类免疫缺陷病毒（HIV-1）逆转录酶抑制剂）单剂量口服给药于HIV-1感染成人的药代动力学：物质平衡研究
Antimicrob Agents Chemother. 1999 Dec;43(12):2855-61. doi: 10.1128/AAC.43.12.2855.
3
Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.阿巴卡韦单药及与齐多夫定联合用药在成人人类免疫缺陷病毒感染者中的多剂量药代动力学和药效学
Antimicrob Agents Chemother. 2000 Aug;44(8):2061-7. doi: 10.1128/AAC.44.8.2061-2067.2000.
4
Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration.HIV 阳性患者每日一次给药后脑脊液中阿巴卡韦浓度。
Br J Clin Pharmacol. 2018 Jun;84(6):1380-1383. doi: 10.1111/bcp.13552. Epub 2018 Mar 15.
5
Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis.1个月至16岁感染人类免疫缺陷病毒儿童的阿巴卡韦药代动力学：一项群体分析。
J Clin Pharmacol. 2005 Mar;45(3):257-64. doi: 10.1177/0091270004272215.
6
Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.HIV感染患者中阿巴卡韦药代动力学的体重相关差异。
Br J Clin Pharmacol. 2005 Feb;59(2):183-8. doi: 10.1111/j.1365-2125.2004.02259.x.
7
8
Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.
Clin Infect Dis. 2001 Oct 15;33(8):e91-2. doi: 10.1086/322682. Epub 2001 Sep 20.
9
Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.来自一项针对人类免疫缺陷病毒感染受试者的剂量范围、双盲、随机单药治疗试验的阿巴卡韦（1592U89）群体药代动力学和药效学建模。
Antimicrob Agents Chemother. 2000 Aug;44(8):2052-60. doi: 10.1128/AAC.44.8.2052-2060.2000.
10
Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid.
J Pharmacol Exp Ther. 2001 Sep;298(3):947-53.
引用本文的文献
1
Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry.超高压液相色谱-串联质谱法测定血浆和脑脊液中的核苷类/核苷酸类逆转录酶抑制剂
Clin Mass Spectrom. 2018 Apr 25;8:8-20. doi: 10.1016/j.clinms.2018.04.001. eCollection 2018 Apr.
2
Antiretroviral Drugs Impact Autophagy: Opportunities for Drug Repurposing.抗逆转录病毒药物对自噬的影响：药物再利用的机会。
Front Biosci (Landmark Ed). 2024 Jul 2;29(7):242. doi: 10.31083/j.fbl2907242.
3
Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies.使用度鲁特韦后的中枢神经系统疾病：来自临床前和临床研究的证据。
Pharmacol Rep. 2023 Oct;75(5):1138-1151. doi: 10.1007/s43440-023-00515-y. Epub 2023 Aug 21.
4
Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs.转运体在抗病毒核苷/核苷酸类似物药代动力学中的重要作用。
Expert Opin Drug Metab Toxicol. 2022 Jul-Aug;18(7-8):483-505. doi: 10.1080/17425255.2022.2112175. Epub 2022 Sep 9.
5
Nucleoside Analogues Are Potent Inducers of Pol V-mediated Mutagenesis.核苷类似物是 Pol V 介导的诱变的有效诱导剂。
Biomolecules. 2021 Jun 5;11(6):843. doi: 10.3390/biom11060843.
6
Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study.HIV 抑制个体中接受抗逆转录病毒药物治疗的鲁索利替尼的药代动力学：来自 ACTG A5336 研究的结果。
J Clin Pharmacol. 2021 Dec;61(12):1555-1566. doi: 10.1002/jcph.1930. Epub 2021 Jul 23.
7
Inhibition of HERV-K (HML-2) in amyotrophic lateral sclerosis patients on antiretroviral therapy.抗逆转录病毒治疗的肌萎缩侧索硬化症患者中 HERV-K（HML-2）的抑制作用。
J Neurol Sci. 2021 Apr 15;423:117358. doi: 10.1016/j.jns.2021.117358. Epub 2021 Feb 23.
8
Pharmacology of HIV Cure: Site of Action.HIV 治愈的药理学：作用部位。
Clin Pharmacol Ther. 2021 Apr;109(4):841-855. doi: 10.1002/cpt.2187. Epub 2021 Mar 5.
9
Pharmacologic approaches to HIV-associated neurocognitive disorders.HIV 相关神经认知障碍的药物治疗方法。
Curr Opin Pharmacol. 2020 Oct;54:102-108. doi: 10.1016/j.coph.2020.09.003. Epub 2020 Oct 10.
10
Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.中枢神经系统药物的临床药代动力学和药效动力学。
Clin Pharmacokinet. 2018 Sep;57(9):1059-1074. doi: 10.1007/s40262-018-0632-y.
本文引用的文献
1
Two phases of HIV RNA decay in CSF during initial days of multidrug therapy.在多药治疗开始的最初几天里，脑脊液中HIV RNA衰变的两个阶段。
Neurology. 2003 Nov 25;61(10):1391-6. doi: 10.1212/wnl.61.10.1391.
2
Roundtable report: importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs.圆桌会议报告：抗逆转录病毒药物浓度在庇护所位点和病毒储存库中的重要性
AIDS Res Hum Retroviruses. 2003 Mar;19(3):167-76. doi: 10.1089/088922203763315669.
3
Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy.在两年治疗期间，血清和脑脊液中齐多夫定、司他夫定、拉米夫定、阿巴卡韦和奈韦拉平的浓度稳定。
Antimicrob Agents Chemother. 2002 Mar;46(3):896-9. doi: 10.1128/AAC.46.3.896-899.2002.
4
Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.
Clin Infect Dis. 2001 Oct 15;33(8):e91-2. doi: 10.1086/322682. Epub 2001 Sep 20.
5
Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.阿巴卡韦单药及与齐多夫定联合用药在成人人类免疫缺陷病毒感染者中的多剂量药代动力学和药效学
Antimicrob Agents Chemother. 2000 Aug;44(8):2061-7. doi: 10.1128/AAC.44.8.2061-2067.2000.
6
Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.来自一项针对人类免疫缺陷病毒感染受试者的剂量范围、双盲、随机单药治疗试验的阿巴卡韦（1592U89）群体药代动力学和药效学建模。
Antimicrob Agents Chemother. 2000 Aug;44(8):2052-60. doi: 10.1128/AAC.44.8.2052-2060.2000.
7
Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources.脑脊液中的HIV RNA来源于局部中枢神经系统和全身各处。
Neurology. 2000 Feb 22;54(4):927-36. doi: 10.1212/wnl.54.4.927.
8
Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study.[(14)C]阿巴卡韦（一种1型人类免疫缺陷病毒（HIV-1）逆转录酶抑制剂）单剂量口服给药于HIV-1感染成人的药代动力学：物质平衡研究
Antimicrob Agents Chemother. 1999 Dec;43(12):2855-61. doi: 10.1128/AAC.43.12.2855.
9
Human immunodeficiency virus-associated dementia: review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy.人类免疫缺陷病毒相关痴呆：齐多夫定治疗的发病机制、预防及治疗研究综述
Clin Infect Dis. 1999 Jul;29(1):19-34. doi: 10.1086/520150.
10
Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine.拉米夫定加齐多夫定或司他夫定治疗后的脑脊液HIV-1 RNA及药物浓度。
Lancet. 1998 May 23;351(9115):1547-51. doi: 10.1016/S0140-6736(98)07333-4.
Zotero 插件